Gossamer bio to present results of torrey fri sub-study at the european respiratory society international congress 2023

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced that data from its functional respiratory imaging, or fri, sub-study of the successful phase 2 torrey study of seralutinib in patients with pah will be presented at the european respiratory society international congress 2023. dr. roham zamanian, profes.
GOSS Ratings Summary
GOSS Quant Ranking